“And so we're confident in this growth acceleration, and we're confident that, that's going to continue beyond the back half of next year.”

In context

“ng in, and I'm sure we'll get into that in the call here with a lot of new approvals plus the prior approvals that we're starting to launch, and they're having meaningful uptake. So there's where the optimism is. In terms of how to think about the back half versus the first-half and then getting into FY ‘25, I'll turn that over to Karen. Karen Parkhill: Yes. Thanks, Geoff and Robbie. So just on the back half, Robbie, our comps do get a little tougher as you know, but we've got a really strong innovation pipeline that we talked about. And that’s driving growth acceleration actually from the first-half to the second-half. We’ve got our diabetes business returning to growth in the second-half, we talked about our extensive pipeline, EV-ICD, PFA, Hugo, Evolut FX,. and now the Ardian approval. And so we're confident in this growth acceleration, and we're confident that, that's going to continue beyond the back half of next year. We think about FY ‘25, you know, it's still early. We have two quarters left in this fiscal year, and we're laser focused on delivering the rest of this year. We're also at the beginning of our planning process, so we're not ready to give specifics. But I do know that all of you are working on your calendar year models for our competitors. So happy to give you some perspective based on what we know today and what we're thinking about. And I'll start with revenue, because we've been focused on consistently delivering that mid-single-digit revenue growth, and you've seen us do that for four quarters now. Our new full-year guide for this fiscal year is 4.75%. And as I mentioned, we've got the strength of those numerous product approvals in big markets that are launching around the world to h”